Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$21.60
+35.8%
$7.04
$4.92
$25.58
$8.70M1.34171,493 shs1.08 million shs
Enerplus Co. stock logo
ERF
Enerplus
$20.09
$20.06
$13.46
$20.97
$4.10B1.973.07 million shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
+11.03%+67.37%+136.61%+188.07%+100.74%
Enerplus Co. stock logo
ERF
Enerplus
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
2.2907 of 5 stars
2.85.00.00.02.40.00.6
Enerplus Co. stock logo
ERF
Enerplus
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.60
Strong Buy$25.0015.74% Upside
Enerplus Co. stock logo
ERF
Enerplus
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ARTL, EGH, ERF, AFA, and PNS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/8/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$20.00
6/11/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/6/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
4/28/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A$5.31 per shareN/A
Enerplus Co. stock logo
ERF
Enerplus
$1.69B2.42$4.23 per share4.75$6.10 per share3.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$9.83M-$17.940.00N/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)
Enerplus Co. stock logo
ERF
Enerplus
$456.08M$1.8011.169.34N/A24.09%33.88%19.89%N/A

Latest ARTL, EGH, ERF, AFA, and PNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$0.78-$4.32-$3.54-$0.72N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
Enerplus Co. stock logo
ERF
Enerplus
$0.261.29%N/A14.44%1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
0.49
0.49
Enerplus Co. stock logo
ERF
Enerplus
0.08
0.70
0.70

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
Enerplus Co. stock logo
ERF
Enerplus
58.42%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.83%
Enerplus Co. stock logo
ERF
Enerplus
0.41%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
5550,000542,000Not Optionable
Enerplus Co. stock logo
ERF
Enerplus
404204.25 million203.41 millionOptionable

Recent News About These Companies

Enerplus Corp Book Value / Share
7 Best Small Company Stocks To Invest In
Enerplus Corporation (ERF.TO)
ERF Stock Earnings: Enerplus Beats EPS for Q1 2024

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$21.60 +5.70 (+35.85%)
Closing price 04:00 PM Eastern
Extended Trading
$21.52 -0.08 (-0.35%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Enerplus stock logo

Enerplus NYSE:ERF

Enerplus Corporation, together with its subsidiaries, explores and develops crude oil and natural gas in the United States. Its oil and natural gas properties are located primarily in North Dakota, Colorado, and Pennsylvania. The company was founded in 1986 and is headquartered in Calgary, Canada.